市場調査レポート
商品コード
999053

再生医療の世界市場 (2020-2030年):製品・用途・17カ国のデータ・競合情勢

Global Regenerative Medicines Market: Focus on Products, Applications, 17 Countries' Data and Competitive Landscape - Analysis and Forecast, 2020-2030

出版日: | 発行: BIS Research Inc. | ページ情報: 英文 264 Pages | 納期: 即日から翌営業日

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=135.61円
再生医療の世界市場 (2020-2030年):製品・用途・17カ国のデータ・競合情勢
出版日: 2021年04月05日
発行: BIS Research Inc.
ページ情報: 英文 264 Pages
納期: 即日から翌営業日
  • 全表示
  • 概要
  • 図表
  • 目次
概要

世界の再生医療の市場規模は予測期間中13.99%のCAGRで推移し、2030年には870億3000万米ドルの規模に成長すると予測されています。

医療業界の大手事業者の統合、再生医療の臨床試験数の増加、承認取得や市場参入促進のための規制環境の整備、幹細胞治療に対する認知度の高まりなどの要因が同市場の成長を推進しています。

当レポートでは、世界の再生医療の市場を調査し、市場の定義と概要、市場成長への各種影響因子の分析、法規制環境、市場規模の推移・予測、製品タイプ・用途・地域/主要国など各種区分別の内訳、競合環境、主要企業のプロファイルなどをまとめています。

第1章 製品の定義・市場の範囲

第2章 調査手法

第3章 市場概要

第4章 市場力学

  • 影響分析
  • 市場推進因子
  • 市場抑制因子
  • 市場機会

第5章 産業考察

  • 概要
  • 法規制の枠組み:米国
  • 法規制の枠組み:欧州
  • 法規制の枠組み:アジア太平洋

第6章 競合考察

  • 概要
  • 提携・協力
  • 製品の承認
  • M&A
  • 事業拡大・資金調達
  • 製品の発売・アップグレード
  • 市場シェア分析
  • 成長シェア分析

第7章 市場分析・予測:製品タイプ別

  • 概要
  • 組織工学
    • 同種異系組織
    • 自家組織
    • 異種組織
    • 合成組織
    • その他
  • 幹細胞
    • 幹細胞サービス
    • 幹細胞治療
  • 細胞・遺伝子治療
    • 細胞治療
    • 遺伝子治療

第8章 市場分析・予測:用途別

  • 概要
  • 整形外科・筋骨格
  • 腫瘍
  • 創傷治療
  • 心臓病
  • 免疫
  • 皮膚科
  • その他

第9章 市場分析・予測:地域・主要国別

  • 概要
  • 北米
    • 米国
    • カナダ
  • 欧州
    • ドイツ
    • フランス
    • イタリア
    • 英国
    • スペイン
    • ロシア
    • オランダ
    • その他
  • アジア太平洋
    • 中国
    • 日本
    • 韓国
    • オーストラリア
    • インド
    • シンガポール
    • その他
  • ラテンアメリカ
    • ブラジル
    • メキシコ
    • その他
  • その他の地域

第10章 企業プロファイル

  • AbbVie, Inc.
  • Baxter International Inc.
  • Becton, Dickinson and Company
  • Dendreon Pharmaceuticals LLC.
  • F. Hoffmann-La Roche Ltd
  • FUJIFILM Holdings Corporation
  • Gilead Sciences, Inc.
  • Integra LifeSciences Holdings Corporation
  • Johnson & Johnson
  • Medtronic plc
  • Mesoblast Ltd
  • Novartis International AG
  • NuVasive, Inc.
  • Organogenesis Holdings Inc.
  • Smith & Nephew plc
  • Stryker Corporation
  • Vericel Corporation
  • Zimmer Biomet Holdings, Inc.
図表

List of Tables

  • Table 3.1: Key Products of Cell and Gene Therapy Market
  • Table 4.1: Impact Analysis
  • Table 4.2: Key Cell and Gene Therapies with FDA Expedited Review
  • Table 4.3: Range of Cost for Regenerative Therapies
  • Table 7.1: List of Key Products
  • Table 7.2: List of Key Products
  • Table 7.3: List of Key Products
  • Table 7.4: List of Key Products
  • Table 7.5: List of Key Products
  • Table 7.6: List of Key Services
  • Table 7.7: List of Key Products
  • Table 7.8: List of Key Products
  • Table 7.9: List of Key Products

List of Figures

  • Figure 1: Global Clinical Landscape for Regenerative Medicine, 2019
  • Figure 2: Impact Analysis on the Global Regenerative Medicines Market
  • Figure 3: Global Regenerative Medicines Market (by Product), $Million, 2019 and 2030
  • Figure 4: Global Regenerative Medicines Market (by Application), $Million, 2019 and 2030
  • Figure 5: Global Regenerative Medicines Market (by Region), Market Snapshot
  • Figure 6: Global Regenerative Medicines Market (by Companies Profiled), Market Snapshot
  • Figure 1.1: Global Regenerative Medicines Market Segmentation

Primary Research Methodology

  • Figure 2.1: Bottom-Up Approach (Segment-Wise Analysis)
  • Figure 2.2: Top-Down Approach (Segment-Wise Analysis)
  • Figure 3.1: Global Regenerative Medicines Market, $Million, 2019-2030
  • Figure 3.2: Impact of COVID-19 on Global Regenerative Medicines Market
  • Figure 4.1: Number of Clinical Trials for ATMP (by Phase), 2019
  • Figure 6.1: Share of Key Developments and Strategies, January 2017-February 2021
  • Figure 6.2: Share of Synergistic Activities, January 2017-February 2021
  • Figure 6.3: Share of Product Approvals (by Company), January 2017-February 2020
  • Figure 6.4: Share of Mergers and Acquisitions (by Company), January 2017-February 2021
  • Figure 6.4: Business Expansion Activities Share, January 2011-February 2021
  • Figure 6.5: Share of Product Launches and Upgradations, January 2017-February 2021
  • Figure 6.6: Market Share Analysis for Global Regenerative Medicines Market (Tissue Engineering), 2019 and 2020
  • Figure 6.7: Market Share Analysis for Global Regenerative Medicines Market (Cell and Gene Therapy), 2019 and 2020
  • Figure 6.8: Market Share Analysis for Global Regenerative Medicines Market (Stem Cell Therapy), 2019 and 2020
  • Figure 6.9: Growth Share Analysis for Global Regenerative Medicines Market (by Company), 2020
  • Figure 6.10: Growth Share Analysis for Global Regenerative Medicines Market (by Product), 2020-2030
  • Figure 6.11: Growth Share Analysis for Global Regenerative Medicines Market (by Application), 2020-2030
  • Figure 7.1: Global Regenerative Medicines Market (by Product Type), $Million, 2019 and 2030
  • Figure 7.2: Global Regenerative Medicines Market (by Tissue Engineering), $Million, 2019-2030
  • Figure 7.3: Global Regenerative Medicines Market (Allogeneic Tissue), $Million, 2019-2030
  • Figure 7.4: Global Regenerative Medicines Market (Autologous Tissue), $Million, 2019-2030
  • Figure 7.5: Global Regenerative Medicines Market (Xenogeneic Tissue), $Million, 2019-2030
  • Figure 7.6: Global Regenerative Medicines Market (Synthetic Tissue), $Million, 2019-2030
  • Figure 7.7: Global Regenerative Medicines Market (Other Tissues), $Million, 2019-2030
  • Figure 7.8: Global Regenerative Medicines Market (by Stem Cells), $Million, 2019-2030
  • Figure 7.9: Global Regenerative Medicines Market (Stem Cell Services), $Million, 2019-2030
  • Figure 7.10: Global Regenerative Medicines Market (Stem Cell Therapy), $Million, 2019-2030
  • Figure 7.11: Global Regenerative Medicines Market (by Cell and Gene Therapy), $Million, 2019-2030
  • Figure 7.12: Global Regenerative Medicines Market (by Cell Therapy), $Million, 2019-2030
  • Figure 7.13: Global Regenerative Medicines Market (by Cell Therapy Type), $Million, 2019 and 2030
  • Figure 7.14: Global Regenerative Medicines Market (Gene Therapy), $Million, 2019-2030
  • Figure 8.1: Global Regenerative Medicines Market (by Application), $Million, 2019 and 2030
  • Figure 8.2: Global Regenerative Medicines Market (Orthopedic and Musculoskeletal), $Million, 2019-2030
  • Figure 8.3: Global Regenerative Medicines Market (Oncology), $Million, 2019-2030
  • Figure 8.4: Global Regenerative Medicines Market (Wound Care), $Million, 2019-2030
  • Figure 8.5: Global Regenerative Medicines Market (Cardiology), $Million, 2019-2030
  • Figure 8.6: Global Regenerative Medicines Market (Immunology), $Million, 2019-2030
  • Figure 8.7: Global Regenerative Medicines Market (Dermatology), $Million, 2019-2030
  • Figure 8.8: Global Regenerative Medicines Market (Other Applications), $Million, 2019-2030
  • Figure 9.1: Global Regenerative Medicines Market (by Region), Market Snapshot
  • Figure 9.2: North America: Market Dynamics
  • Figure 9.3: North America Regenerative Medicines Market, $Million, 2019-2030
  • Figure 9.4: North America Regenerative Medicines Market (by Country), $Million, 2019 Vs. 2030
  • Figure 9.5: U.S. Regenerative Medicines Market, $Million, 2019-2030
  • Figure 9.6: U.S. Regenerative Medicines Market (by Product), $Million, 2019-2030
  • Figure 9.7: Canada Regenerative Medicines Market, $Million, 2019-2030
  • Figure 9.8: Canada Regenerative Medicines Market (by Product), $Million, 2019-2030
  • Figure 9.9: Europe: Market Dynamics
  • Figure 9.10: Europe Regenerative Medicines Market, $Million, 2019-2030
  • Figure 9.11: Europe Regenerative Medicines Market (by Country), $Million, 2019 Vs. 2030
  • Figure 9.12: Germany Regenerative Medicines Market, $Million, 2019-2030
  • Figure 9.13: Germany Regenerative Medicines Market (by Product), $Million, 2019-2030
  • Figure 9.14: France Regenerative Medicines Market, $Million, 2019-2030
  • Figure 9.15: France Regenerative Medicines Market (by Product), $Million, 2019-2030
  • Figure 9.16: Italy Regenerative Medicines Market, $Million, 2019-2030
  • Figure 9.17: Italy Regenerative Medicines Market (by Product), $Million, 2019-2030
  • Figure 9.18: U.K. Regenerative Medicines Market, $Million, 2019-2030
  • Figure 9.19: U.K. Regenerative Medicines Market (by Product), $Million, 2019-2030
  • Figure 9.20: Spain Regenerative Medicines Market, $Million, 2019-2030
  • Figure 9.21: Spain Regenerative Medicines Market (by Product), $Million, 2019-2030
  • Figure 9.22: Russia Regenerative Medicines Market, $Million, 2019-2030
  • Figure 9.23: Russia Regenerative Medicines Market (by Product), $Million, 2019-2030
  • Figure 9.24: Netherlands Regenerative Medicines Market, $Million, 2019-2030
  • Figure 9.25: Netherlands Regenerative Medicines Market (by Product), $Million, 2019-2030
  • Figure 9.26: Rest-of-Europe Regenerative Medicines Market, $Million, 2019-2030
  • Figure 9.27: Rest-of-Europe Regenerative Medicines Market (by Product), $Million, 2019-2030
  • Figure 9.28: Asia-Pacific: Market Dynamics
  • Figure 9.29: Asia-Pacific Regenerative Medicines Market, $Million, 2019-2030
  • Figure 9.30: Asia-Pacific Regenerative Medicines Market (by Country), $Million, 2019 Vs. 2030
  • Figure 9.31: China Regenerative Medicines Market, $Million, 2019-2030
  • Figure 9.32: China Regenerative Medicines Market (by Product), $Million, 2019-2030
  • Figure 9.33: Japan Regenerative Medicines Market, $Million, 2019-2030
  • Figure 9.34: Japan Regenerative Medicines Market (by Product), $Million, 2019-2030
  • Figure 9.35: South Korea Regenerative Medicines Market, $Million, 2019-2030
  • Figure 9.36: South Korea Regenerative Medicines Market (by Product), $Million, 2019-2030
  • Figure 9.37: Australia Regenerative Medicines Market, $Million, 2019-2030
  • Figure 9.38: Australia Regenerative Medicines Market (by Product), $Million, 2019-2030
  • Figure 9.39: India Regenerative Medicines Market, $Million, 2019-2030
  • Figure 9.40: India Regenerative Medicines Market (by Product), $Million, 2019-2030
  • Figure 9.41: Singapore Regenerative Medicines Market, $Million, 2019-2030
  • Figure 9.42: Singapore Regenerative Medicines Market (by Product), $Million, 2019-2030
  • Figure 9.43: Rest-of-Asia-Pacific Regenerative Medicines Market, $Million, 2019-2030
  • Figure 9.44: Rest-of-Asia-Pacific Regenerative Medicines Market (by Product), $Million, 2019-2030
  • Figure 9.45: Latin America: Market Dynamics
  • Figure 9.46: Latin America Regenerative Medicines Market, $Million, 2019-2030
  • Figure 9.47: Latin America Regenerative Medicines Market (by Country), $Million, 2019 Vs. 2030
  • Figure 9.48: Brazil Regenerative Medicines Market, $Million, 2019-2030
  • Figure 9.49: Brazil Regenerative Medicines Market (by Product), $Million, 2019-2030
  • Figure 9.50: Mexico Regenerative Medicines Market, $Million, 2019-2030
  • Figure 9.51: Mexico Regenerative Medicines Market (by Product), $Million, 2019-2030
  • Figure 9.52: Rest-of-Latin America Regenerative Medicines Market, $Million, 2019-2030
  • Figure 9.53: Rest-of-Latin America Regenerative Medicines Market (by Product), $Million, 2019-2030
  • Figure 9.54: Rest-of-the-World Regenerative Medicines Market, $Million, 2019-2030
  • Figure 10.1: Total Number of Companies Profiled
  • Figure 10.2: AbbVie, Inc.: Overall Product Portfolio
  • Figure 10.3: AbbVie, Inc.: Overall Financials, 2018-2020
  • Figure 10.4: AbbVie, Inc.: Revenue (by Segment), 2018-2020
  • Figure 10.5: AbbVie, Inc.: Revenue (by Region), 2018-2020
  • Figure 10.6: AbbVie, Inc.: R&D Expenditure, 2018-2020
  • Figure 10.7: AbbVie, Inc.: SWOT Analysis
  • Figure 10.8: Baxter International Inc.: Overall Product Portfolio
  • Figure 10.9: Baxter International Inc.: Overall Financials, 2018-2020
  • Figure 10.10: Baxter International Inc.: Revenue (by Segment), 2018-2020
  • Figure 10.11: Baxter International Inc.: Revenue (by Region), 2018-2020
  • Figure 10.12: Baxter International Inc.: R&D Expenditure, 2018-2020
  • Figure 10.13: bioMerieux SA: SWOT Analysis
  • Figure 10.14: Becton, Dickinson and Company: Overall Service Portfolio
  • Figure 10.15: Becton, Dickinson and Company.: Overall Financials, 2018-2020
  • Figure 10.16: Becton, Dickinson and Company: Revenue (by Segment), 2018-2020
  • Figure 10.17: Becton, Dickinson and Company: Revenue (by Region), 2017-2019
  • Figure 10.18: Becton, Dickinson and Company: R&D Expenditure, 2018-2020
  • Figure 10.19: Becton, Dickinson and Company: SWOT Analysis
  • Figure 10.20: Dendreon Pharmaceuticals LLC.: Product Portfolio
  • Figure 10.21: Dendreon Pharmaceuticals LLC.: SWOT Analysis
  • Figure 10.22: F. Hoffmann-La Roche Ltd.: Overall Product Portfolio
  • Figure 10.23: F. Hoffmann-La Roche Ltd.: Pipeline Portfolio
  • Figure 10.24: F. Hoffmann-La Roche Ltd.: Overall Financials, 2018-2020
  • Figure 10.25: F. Hoffmann-La Roche Ltd.: Revenue (by Segment), 2018-2020
  • Figure 10.26: F. Hoffmann-La Roche Ltd.: Revenue (by Region), 2018-2020
  • Figure 10.27: F. Hoffmann-La Roche Ltd.: R&D Expenditure, 2018-2020
  • Figure 10.28: F. Hoffmann-La Roche Ltd.: SWOT Analysis
  • Figure 10.29: FUJIFILM Holdings Corporation: Overall Product Portfolio
  • Figure 10.30: FUJIFILM Holdings Corporation: Overall Financials, 2017-2019
  • Figure 10.31: FUJIFILM Holdings Corporation: Revenue (by Segment), 2017-2019
  • Figure 10.32: FUJIFILM Holdings Corporation: Revenue (by Region), 2017-2019
  • Figure 10.33: FUJIFILM Holdings Corporation: R&D Expenditure, 2017-2019
  • Figure 10.34: FUJIFILM Holdings Corporation: SWOT Analysis
  • Figure 10.35: Gilead Sciences, Inc.: Product Portfolio
  • Figure 10.36: Gilead Sciences, Inc.: Pipeline Product Portfolio
  • Figure 10.37: Gilead Sciences, Inc.: Overall Financials, 2018-2020
  • Figure 10.38: Gilead Sciences, Inc.: Revenue (by Segment), 2018-2020
  • Figure 10.39: Gilead Sciences, Inc.: Revenue (by Region), 2018-2020
  • Figure 10.40: Gilead Sciences, Inc.: R&D Expenditure, 2018-2020
  • Figure 10.41: Gilead Sciences, Inc.: SWOT Analysis
  • Figure 10.42: Integra LifeSciences Holdings Corporation: Overall Product Portfolio
  • Figure 10.43: Integra LifeSciences Holdings Corporation: Overall Financials, 2018-2020
  • Figure 10.44: Integra LifeSciences Holdings Corporation: Revenue (by Segment), 2018-2020
  • Figure 10.45: Integra LifeSciences Holdings Corporation: Revenue (by Region), 2018-2020
  • Figure 10.46: Integra LifeSciences Holdings Corporation: R&D Expenditure, 2018-2020
  • Figure 10.47: Integra LifeSciences Holdings Corporation: SWOT Analysis
  • Figure 10.48: Johnson & Johnson: Product Portfolio
  • Figure 10.49: Johnson & Johnson: Overall Financials, 2018-2020
  • Figure 10.50: Johnson & Johnson: Revenue (by Segment), 2018-2020
  • Figure 10.51: Johnson & Johnson: Revenue (by Region), 2018-2020
  • Figure 10.52: Johnson & Johnson: R&D Expenditure, 2018-2020
  • Figure 10.53: Johnson & Johnson: SWOT Analysis
  • Figure 10.54: Medtronic plc: Product Portfolio
  • Figure 10.55: Medtronic plc: Overall Financials, 2018-2020
  • Figure 10.56: Medtronic plc: Revenue (by Segment), 2018-2020
  • Figure 10.57: Medtronic plc: Revenue (by Restorative Therapies Group), 2018-2020
  • Figure 10.58: Medtronic plc: Revenue (by Region), 2018-2020
  • Figure 10.59: Medtronic plc: R&D Expenditure, 2018-2020
  • Figure 10.60: Medtronic plc: SWOT Analysis
  • Figure 10.61: Mesoblast Ltd.: Product Portfolio
  • Figure 10.62: Mesoblast Ltd.: Product Portfolio
  • Figure 10.62: Mesoblast Ltd: Overall Financials, 2018-2020
  • Figure 10.63: Mesoblast Ltd: Revenue (by Segment), 2018-2020
  • Figure 10.64: Mesoblast Ltd: R&D Expenditure, 2018-2020
  • Figure 10.65: Mesoblast Ltd: SWOT Analysis
  • Figure 10.66: Novartis International AG: Product Portfolio
  • Figure 10.67: Novartis International AG: Pipeline Product Portfolio
  • Figure 10.68: Novartis International AG.: Overall Financials, 2018-2020
  • Figure 10.69: Novartis International AG: Revenue (by Segment), 2018-2020
  • Figure 10.70: Novartis International AG: Revenue (by Region), 2018-2020
  • Figure 10.71: Novartis International AG: R&D Expenditure, 2018-2020
  • Figure 10.72: Novartis International AG: SWOT Analysis
  • Figure 10.73: NuVasive, Inc.: Product Portfolio
  • Figure 10.74: NuVasive, Inc.: Overall Financials, 2018-2020
  • Figure 10.75: NuVasive, Inc.: Revenue (by Segment), 2018-2020
  • Figure 10.76: NuVasive, Inc.: Revenue (by Region), 2018-2020
  • Figure 10.77: NuVasive, Inc.: R&D Expenditure, 2018-2020
  • Figure 10.78: NuVasive, Inc.: SWOT Analysis
  • Figure 10.79: Organogenesis Holdings Inc.: Product Portfolio
  • Figure 10.80: Organogenesis Holdings Inc.: Overall Financials, 2017-2019
  • Figure 10.81: Organogenesis Holdings Inc.: Revenue (by Segment), 2017-2019
  • Figure 10.82: Organogenesis Holdings Inc.: R&D Expenditure, 2017-2019
  • Figure 10.83: Organogenesis Holdings Inc.: SWOT Analysis
  • Figure 10.84: Smith & Nephew plc: Product Portfolio
  • Figure 10.85: Smith & Nephew plc: Overall Financials, 2018-2020
  • Figure 10.86: Smith & Nephew plc: Revenue (by Segment), 2018-2020
  • Figure 10.87: Smith & Nephew plc: Revenue (by Region), 2018-2020
  • Figure 10.88: Smith & Nephew plc: R&D Expenditure, 2018-2020
  • Figure 10.89: Smith & Nephew plc: SWOT Analysis
  • Figure 10.90: Stryker Corporation: Product Portfolio
  • Figure 10.91: Stryker Corporation: Overall Financials, 2018-2020
  • Figure 10.92: Stryker Corporation: Revenue (by Segment), 2018-2020
  • Figure 10.93: Stryker Corporation: Revenue (by Region), 2018-2020
  • Figure 10.94: Stryker Corporation: R&D Expenditure, 2018-2020
  • Figure 10.95: Stryker Corporation: SWOT Analysis
  • Figure 10.96: Vericel Corporation: Product Portfolio
  • Figure 10.97: Vericel Corporation: Overall Financials, 2018-2020
  • Figure 10.98: Vericel Corporation: Revenue (by Segment), 2018-2020
  • Figure 10.99: Vericel Corporation: R&D Expenditure, 2018-2020
  • Figure 10.100: Vericel Corporation: SWOT Analysis
  • Figure 10.101: Zimmer Biomet Holdings, Inc.: Product Portfolio
  • Figure 10.102: Zimmer Biomet Holdings, Inc.: Overall Financials, 2018-2020
  • Figure 10.103: Zimmer Biomet Holdings, Inc.: Revenue (by Segment), 2018-2020
  • Figure 10.104: Zimmer Biomet Holdings, Inc.: Revenue (by Region), 2018-2020
  • Figure 10.105: Zimmer Biomet Holdings, Inc.: R&D Expenditure, 2018-2020
  • Figure 10.106: Zimmer Biomet Holdings, Inc.: SWOT Analysis
目次
Product Code: BHP0544SB

“Global Regenerative Medicines Market to Reach $87.03 Billion by 2030.”

Market Report Coverage - Regenerative Medicines

Market Segmentation

  • Product - Tissue Engineering (Allogeneic Tissue, Autologous Tissue, Xenogeneic Tissue, and Synthetic Tissue), Stem Cells (Stem Cell Services and Stem Cell Therapies), and Cell ang Gene Therapy (Car-T Cell Therapy, Gene Therapy, Other Cell Therapies)
  • Application - Orthopedic and Musculoskeletal, Oncology, Wound Care, Cardiology, Immunology, Dermatology, and Other Applications

Regional Segmentation

  • North America - U.S., and Canada
  • Europe - Germany, U.K., France, Italy, Spain, Netherlands, Russia, and Rest-of-Europe
  • Asia-Pacific - China, Japan, India, Australia, South Korea, Singapore, and Rest-of-Asia-Pacific
  • Latin America - Brazil, Mexico, and Rest-of-Latin America
  • Rest-of-the-World

Growth Drivers

  • Increasing Consolidation Among Healthcare Juggernauts
  • Rising Number of Clinical Trials for Regenerative Therapies
  • A Favorable Regulatory Environment to Accelerate Approvals and Market Entry
  • A Rising Awareness for Stem Cell Therapeutics

Market Challenges

  • Lack of Reliable Vector Production for Cell and Gene Therapy
  • Exorbitant Cost of Next-Generation Therapies

Market Opportunities

  • Drug Approvals and Strong Pipeline of Cell and Gene Therapies
  • Multiple Investments in Expansion of cGMP Units
  • Innovations in Regenerative Medicine

Key Companies Profiled

AbbVie, Inc., Baxter International Inc., Becton, Dickinson and Company, Dendreon Pharmaceuticals LLC, F. Hoffmann-La Roche Ltd., FUJIFILM Holdings Corporation, Gilead Sciences, Inc., Integra LifeSciences Holdings Corporation, Johnson & Johnson, Medtronic plc, Mesoblast Ltd., Novartis International A.G., NuVasive, Inc., Organogenesis Holdings, Inc., Smith & Nephew plc, Stryker Corporation, Vericel Corporation, and Zimmer Biomet Holdings, Inc.

Key Questions Answered in this Report:

  • What are the major market drivers, challenges, and opportunities and their respective impacts on the global regenerative medicines market?
  • What is the potential impact of advancement in therapeutics among emerging segments of the global regenerative medicines market?
  • What is the current market demand along with future demand for the global regenerative medicines market?
  • What are the key regulatory hurdles for industry players looking to enter this highly dynamic market?
  • What are the key development strategies that are implemented by the major players in order to sustain the competitive market?
  • How is each of the segments of the market expected to grow during the forecast period from 2020 to 2030 based on each segment? Following are the segments:
    • Product
    • Application
    • Regions, namely, North America, Europe, Asia-Pacific, Latin America, and Rest-of-the-World (RoW)
  • Who are the leading players with significant offerings to the global regenerative medicines market? What is the expected market share for each of these leading players?
  • Which emerging companies are anticipated to be highly disruptive in the future, and what are their key strategies for sustainable growth in the global regenerative medicines market?
  • How is the underlying cell and gene therapy segment pushing the boundaries of regenerative medicine across the world? What are the next-generation therapies within this segment?

Market Overview

BIS healthcare experts have found cell and gene therapy to be one of the most rapidly evolving and dynamic markets, and the global market for regenerative medicines is predicted to grow at a CAGR of 13.99% over the forecast period of 2020-2030. The market is driven by certain factors, including increasing consolidation among healthcare juggernauts, rising number of clinical trials for regenerative therapies, a favorable regulatory environment to accelerate approvals and market entry, and rising awareness for stem cell therapeutics, that are fueling the growth of the global regenerative medicines market.

Regenerative medicine is challenging the current healthcare practices by targeting the treatment of the root causes of disease and disorders, transforming it into an incredibly exciting space. However, these advancements have not come without significant challenges and uncertainties, which will also further need to be overcome to realize the full potential of regenerative medicine.

Cell and gene therapies, under the regenerative umbrella, are slowly and steadily becoming a healthcare standard, particularly in developed regions such as the U.S. and Europe, where already established markets for tissue engineering and stem cell have largely been responsible for driving the global regenerative medicine phenomenon. Cell and gene therapies, though advancing at a rapid pace, have primarily been targeted for hematological malignancies. However, the same potential has not been replicated in solid tumor applications, consequently creating demand for cell therapies focusing on solid tumors. As a result, the industry is now moving toward the research and subsequent clinical translation of next-generation therapies, led by natural killer (NK) cells, which offer a viable option for solid tumors as well. Such trends are consistently propelling the industry toward realizing the true potential of precision medicine.

Within the research report, the market is segmented on the basis of products, applications, and region. Each of these segments covers the snapshot of the market over the projected years, the inclination of the market revenue, underlying patterns, and trends by using analytics on the primary and secondary data obtained.

Competitive Landscape

The global regenerative medicines market is currently witnessing several developments, primarily aimed toward bringing new products to support clinicians for the treatment of life-threatening disorders. Major manufacturers of regenerative medicine products are actively involved in undertaking significant business strategies in order to translate success in research and development into the commercial clinical setting. Although tissue engineering and stem cells remain the dominating product segments, the advent of cell and gene therapy has revolutionized the regenerative medicine phenomenon, moving it more toward the precision medicine space.

On the basis of region, North America holds the largest share of the regenerative medicines market due to a high number of active advanced therapeutic medicinal product trials, massive government funding, expansion activities by major companies, and an overall high adoption rate for advancing therapies. Apart from this, the Asia-Pacific region is anticipated to grow at the fastest CAGR during the forecast period, 2020-2030.

Table of Contents

Executive Summary

1 Product Definition and Market Scope

  • 1.1 Inclusion and Exclusion
  • 1.2 Scope of Work
  • 1.3 Key Questions Answered in the Report

2 Research Methodology

  • 2.1 Primary Data Sources
  • 2.2 Secondary Data Sources
  • 2.3 Market Estimation Model
  • 2.4 Criteria for Company Profiling

3 Market Overview

  • 3.1 Clinical Importance of Regenerative Medicine
  • 3.2 Market Footprint
  • 3.3 Impact of COVID-19

4 Market Dynamics

  • 4.1 Impact Analysis
  • 4.2 Market Drivers
    • 4.2.1 Increasing Consolidation in the Regenerative Medicines Market
    • 4.2.2 Rising Number of Clinical Trials
    • 4.2.3 Favorable Regulatory Environment
    • 4.2.4 Rising Awareness for Stem Cell Therapeutics
  • 4.3 Market Restraints
    • 4.3.1 Lack of Reliable Vector Production for Cell and Gene Therapy
    • 4.3.2 Exorbitant Cost of Next-Generation Therapies
  • 4.4 Opportunities
    • 4.4.1 Drug Approvals and Strong Pipeline of Cell and Gene Therapies
    • 4.4.2 Multiple Investments in Expansion of cGMP Units
    • 4.4.3 Innovations in Regenerative Medicine

5 Industry Insights

  • 5.1 Overview
  • 5.2 Legal and Regulatory Framework in the U.S.
    • 5.2.1 Cell and Gene Therapy
      • 5.2.1.1 Cell and Gene Therapy Manufacturing QC
        • 5.2.1.1.1 Product Testing
          • 5.2.1.1.1.1 Microbial Testing
          • 5.2.1.1.1.2 Identity
          • 5.2.1.1.1.3 Purity
          • 5.2.1.1.1.4 Potency
          • 5.2.1.1.1.5 Viability
          • 5.2.1.1.1.6 Cell Number/Dose
    • 5.2.2 Stem Cell Therapy
    • 5.2.3 Tissue-Engineered Products
  • 5.3 Legal and Regulatory Framework in Europe
  • 5.4 Legal and Regulatory Framework in Asia-Pacific
    • 5.4.1 China
    • 5.4.2 Japan

6 Global Regenerative Medicines Market: Competitive Insights

  • 6.1 Overview
  • 6.2 Synergistic Activities
  • 6.3 Product Approval
  • 6.4 Mergers and Acquisitions
  • 6.5 Business Expansion and Funding
  • 6.6 Product Launches and Upgradations
  • 6.7 Market Share Analysis, 2019-2020
    • 6.7.1 Market Share Analysis for Global Regenerative Medicines Market (Tissue Engineering), 2019-2020
    • 6.7.2 Market Share Analysis for Global Regenerative Medicines Market (Cell and Gene Therapy), 2019-2020
    • 6.7.3 Market Share Analysis for Global Regenerative Medicines Market (Stem Cell Therapy), 2019-2020
  • 6.8 Growth Share Analysis
    • 6.8.1 Growth Share Analysis (by Company)
    • 6.8.2 Growth Share Analysis (by Product)
    • 6.8.3 Growth Share Analysis (by Application)

7 Global Regenerative Medicines Market (by Product Type), $Million, 2019-2030

  • 7.1 Overview
  • 7.2 Tissue Engineering
    • 7.2.1 Allogeneic Tissue
    • 7.2.2 Autologous Tissue
    • 7.2.3 Xenogeneic Tissue
    • 7.2.4 Synthetic Tissue
    • 7.2.5 Other Tissues
  • 7.3 Stem Cells
    • 7.3.1 Stem Cell Services
    • 7.3.2 Stem Cell Therapy
  • 7.4 Cell and Gene Therapy
    • 7.4.1 Cell Therapy
      • 7.4.1.1 Cell Therapy (by Type)
    • 7.4.2 Gene Therapy

8 Global Regenerative Medicines Market (by Application), $Million, 2019-2030

  • 8.1 Overview
  • 8.2 Orthopedic and Musculoskeletal
  • 8.3 Oncology
  • 8.4 Wound Care
  • 8.5 Cardiology
  • 8.6 Immunology
  • 8.7 Dermatology
  • 8.8 Other Applications

9 Global Regenerative Medicines Market (by Region), $Million, 2019-2030

  • 9.1 Overview
  • 9.2 North America
    • 9.2.1 U.S.
    • 9.2.2 Canada
  • 9.3 Europe
    • 9.3.1 Germany
    • 9.3.2 France
    • 9.3.3 Italy
    • 9.3.4 U.K.
    • 9.3.5 Spain
    • 9.3.6 Russia
    • 9.3.7 Netherlands
    • 9.3.8 Rest-of-Europe
  • 9.4 Asia-Pacific
    • 9.4.1 China
    • 9.4.2 Japan
    • 9.4.3 South Korea
    • 9.4.4 Australia
    • 9.4.5 India
    • 9.4.6 Singapore
    • 9.4.7 Rest-of-Asia-Pacific
  • 9.5 Latin America
    • 9.5.1 Brazil
    • 9.5.2 Mexico
    • 9.5.3 Rest-of-Latin America
  • 9.6 Rest-of-the-World (RoW)

10 Company Profiles

  • 10.1 Overview
  • 10.2 AbbVie, Inc.
    • 10.2.1 Company Overview
    • 10.2.2 Role of AbbVie, Inc. in Global Regenerative Medicines Market
    • 10.2.3 Financials
    • 10.2.4 Key Insights About Financial Health of the Company
    • 10.2.5 SWOT Analysis
  • 10.3 Baxter International Inc.
    • 10.3.1 Company Overview
    • 10.3.2 Role of Baxter International Inc. in Global Regenerative Medicines Market
    • 10.3.3 Financials
    • 10.3.4 Key Insights About Financial Health of the Company
    • 10.3.5 SWOT Analysis
  • 10.4 Becton, Dickinson and Company
    • 10.4.1 Company Overview
    • 10.4.2 Role of Becton, Dickinson and Company in the Global Regenerative Medicines Market
    • 10.4.3 Financials
    • 10.4.4 Key Insights About Financial Health of the Company
    • 10.4.5 SWOT Analysis
  • 10.5 Dendreon Pharmaceuticals LLC.
    • 10.5.1 Company Overview
    • 10.5.2 Role of Dendreon Pharmaceuticals LLC. in the Global Regenerative Medicines Market
    • 10.5.3 SWOT Analysis
  • 10.6 F. Hoffmann-La Roche Ltd
    • 10.6.1 Company Overview
    • 10.6.2 Role of F. Hoffmann-La Roche Ltd. in the Global Regenerative Medicines Market
    • 10.6.3 Financials
    • 10.6.4 Key Insights About Financial Health of the Company
    • 10.6.5 SWOT Analysis
  • 10.7 FUJIFILM Holdings Corporation
    • 10.7.1 Company Overview
    • 10.7.2 Role of FUJIFILM Holdings Corporation in the Global Regenerative Medicines Market
    • 10.7.3 Financials
    • 10.7.4 Key Insights About Financial Health of the Company
    • 10.7.5 SWOT Analysis
  • 10.8 Gilead Sciences, Inc.
    • 10.8.1 Company Overview
    • 10.8.2 Role of Gilead Sciences, Inc. in the Global Regenerative Medicines Market
    • 10.8.3 Financials
    • 10.8.4 Key Insights About Financial Health of the Company
    • 10.8.5 SWOT Analysis
  • 10.9 Integra LifeSciences Holdings Corporation
    • 10.9.1 Company Overview
    • 10.9.2 Role of Integra LifeSciences Holdings Corporation in Global Regenerative Medicines Market
    • 10.9.3 Financials
    • 10.9.4 Key Insights About Financial Health of the Company
    • 10.9.5 SWOT Analysis
  • 10.1 Johnson & Johnson
    • 10.10.1 Company Overview
    • 10.10.2 Role of Johnson & Johnson in the Global Regenerative Medicines Market
    • 10.10.3 Financials
    • 10.10.4 Key Insights About Financial Health of the Company
    • 10.10.5 SWOT Analysis
  • 10.11 Medtronic plc
    • 10.11.1 Company Overview
    • 10.11.2 Role of Medtronic plc in the Global Regenerative Medicines Market
    • 10.11.3 Financials
    • 10.11.4 Key Insights About Financial Health of the Company
    • 10.11.5 SWOT Analysis
  • 10.12 Mesoblast Ltd
    • 10.12.1 Company Overview
    • 10.12.2 Role of Mesoblast Ltd in the Global Regenerative Medicines Market
    • 10.12.3 Financials
    • 10.12.4 Key Insights About Financial Health of the Company
    • 10.12.5 SWOT Analysis
  • 10.13 Novartis International AG
    • 10.13.1 Company Overview
    • 10.13.2 Role of Novartis International AG in the Global Regenerative Medicines Market
    • 10.13.3 Financials
    • 10.13.4 Key Insights About Financial Health of the Company
    • 10.13.5 SWOT Analysis
  • 10.14 NuVasive, Inc.
    • 10.14.1 Company Overview
    • 10.14.2 Role of NuVasive, Inc. in the Global Regenerative Medicines Market
    • 10.14.3 Financials
    • 10.14.4 Key Insights About Financial Health of the Company
    • 10.14.5 SWOT Analysis
  • 10.15 Organogenesis Holdings Inc.
    • 10.15.1 Company Overview
    • 10.15.2 Role of Organogenesis Holdings, Inc. in the Global Regenerative Medicines Market
    • 10.15.3 Financials
    • 10.15.4 Key Insights About the Financial Health of the Company
    • 10.15.5 SWOT Analysis
  • 10.16 Smith & Nephew plc
    • 10.16.1 Company Overview
    • 10.16.2 Role of Smith & Nephew plc in the Global Regenerative Medicines Market
    • 10.16.3 Financials
    • 10.16.4 Key Insights About Financial Health of the Company
    • 10.16.5 SWOT Analysis
  • 10.17 Stryker Corporation
    • 10.17.1 Company Overview
    • 10.17.2 Role of Stryker Corporation in the Global Regenerative Medicines Market
    • 10.17.3 Financials
    • 10.17.4 Key Insights About Financial Health of the Company
    • 10.17.5 SWOT Analysis
  • 10.18 Vericel Corporation
    • 10.18.1 Company Overview
    • 10.18.2 Role of Vericel Corporation in the Global Regenerative Medicines Market
    • 10.18.3 Financials
    • 10.18.4 Key Insights About Financial Health of the Company
    • 10.18.5 SWOT Analysis
  • 10.19 Zimmer Biomet Holdings, Inc.
    • 10.19.1 Company Overview
    • 10.19.2 Role of Zimmer Biomet Holdings, Inc. in the Global Regenerative Medicines Market
    • 10.19.3 Financials
    • 10.19.4 Key Insights About Financial Health of the Company
    • 10.19.5 SWOT Analysis